Journal publications

Export 73 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
Bansi L, Smith C, Phillips AN, Kirk S., Geretti AM, Johnson M, Mackie N, Post FA, Gazzard B, Dunn DT et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Dunn DT, Coughlin K., Cane P A.  2011.  Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn DT, Paredes R, Sabin CA, Lundgren J, Phillips AN, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S.  2010.  Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC).  2010.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Harrison LJ, Castro H, Cane P A, Pillay D, Booth C, Phillips AN, Geretti AM, Dunn DT.  2010.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.
Dunn DT, von Wyl V., Price H., Asboe D.  2010.  The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.
Bansi L, Geretti AM, Dunn DT, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips AN et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
de Oliveira T, Pillay D, Gifford RJM.  2010.  The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn DT.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.
Price H., Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn DT.  2010.  Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther. 15:203-11.
Hughes GJ, Fearnhill E, Dunn DT, Lycett S, Rambaut A, Leigh Brown A.  2009.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.
Harrison LJ, Dunn DT, Green H, Copas A.  2009.  Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.
Pond S.LKosakov, Posada D., Stawiski E., Chappey C., Poon A.F, Hughes GJ, Fearnhill E, Gravenor M.B, Leigh Brown A, Frost S.D.  2009.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.
Geretti AM, Harrison LJ, Green H, Sabin CA, Hill T, Fearnhill E, Pillay D, Dunn DT.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.
Hue S, Gifford RJM, Dunn DT, Fearnhill E, Pillay D.  2009.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol. 83:2645-54.
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S, Lima V.D, Günthard HF, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.
Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT.  2008.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.